Rapid elicitation of a new class of neutralizing N332-glycan independent V3-glycan antibodies against HIV-1 in nonhuman primates.
Relano-Rodriguez, I.; Du, J.; Lin, Z. J.; Kerwin, M.; Tarquis-Medina, M.; Urbano, E.; Cui, J.; Watkins, M.; Zhao, P.; Habib, R.; Gosh, S.; Park, J.; Boroughs, C.; Walsh, A. A.; Melo, M. B.; Shaw, G. M.; Hahn, B. H.; Irvine, D. J.; Wells, L.; Weiner, D. B.; Kulp, D. W.; Veazey, R. S.; Pallesen, J.; Escolano, A.
Show abstract
Sequential immunization is a promising approach to elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 Envelope (Env). However, available protocols are inefficient and involve multiple immunizations over long periods of time. Here, we present WIN332, a new engineered Env-immunogen that induces a new class of neutralizing N332-glycan-independent antibodies to the conserved V3-glycan epitope of Env after a single bolus immunization in nonhuman primates. WIN332 binds to precursors of canonical human N332-glycan-dependent (Type-I) V3-glycan bNAbs but also of a first-of-its-class N332-glycan-independent (Type-II) V3-glycan bNAb. A single immunization elicits neutralizing serum and monoclonal antibodies that are boosted and affinity matured with a heterologous immunogen. EMPEM analysis of serum antibodies, antibody cloning and cryo-EM analysis reveal that WIN332 elicits N332-glycan-independent antibodies with remarkable sequence and binding similarities with the most potent human type-I and type-II V3-glycan bNAbs. Thus, WIN332 is a promising vaccine candidate to streamline V3-glycan bNAb elicitation.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design 99%
- Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3 99%
- Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2 99%
Similar papers in this journal
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals 98%
- SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies 97%
- A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron 97%
Similar papers in this journal
Similar papers in this journal
- Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals 98%
- Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants 98%
- Transient glycan-shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques 97%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.